You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Bapineuzumab for mild to moderate Alzheimer’s disease in two global, randomized, phase 3 trials
|
|---|---|
| Published in |
Alzheimer's Research & Therapy, May 2016
|
| DOI | 10.1186/s13195-016-0189-7 |
| Pubmed ID | |
| Authors |
Rik Vandenberghe, Juha O. Rinne, Mercè Boada, Sadao Katayama, Philip Scheltens, Bruno Vellas, Michael Tuchman, Achim Gass, Jochen B. Fiebach, Derek Hill, Kasia Lobello, David Li, Tom McRae, Prisca Lucas, Iona Evans, Kevin Booth, Gerald Luscan, Bradley T. Wyman, Lisa Hua, Lingfeng Yang, H. Robert Brashear, Ronald S. Black, for the Bapineuzumab 3000 and 3001 Clinical Study Investigators |
| Abstract |
Our objective was to evaluate the efficacy (clinical and biomarker) and safety of intravenous bapineuzumab in patients with mild to moderate Alzheimer's disease (AD). Two of four phase 3, multicenter, randomized, double-blind, placebo-controlled, 18-month trials were conducted globally: one in apolipoprotein E ε4 carriers and another in noncarriers. Patients received bapineuzumab 0.5 mg/kg (both trials) or 1.0 mg/kg (noncarrier trial) or placebo every 13 weeks. Coprimary endpoints were change from baseline to week 78 on the 11-item Alzheimer's Disease Assessment Scale-Cognitive subscale and the Disability Assessment for Dementia. A total of 683 and 329 patients completed the current carrier and noncarrier trials, respectively, which were terminated prematurely owing to lack of efficacy in the two other phase 3 trials of bapineuzumab in AD. The current trials showed no significant difference between bapineuzumab and placebo for the coprimary endpoints and no effect of bapineuzumab on amyloid load or cerebrospinal fluid phosphorylated tau. (Both measures were stable over time in the placebo group.) Amyloid-related imaging abnormalities with edema or effusion were confirmed as the most notable adverse event. These phase 3 global trials confirmed lack of efficacy of bapineuzumab at tested doses on clinical endpoints in patients with mild to moderate AD. Some differences in the biomarker results were seen compared with the other phase 3 bapineuzumab trials. No unexpected adverse events were observed. Noncarriers (3000) ClinicalTrials.gov identifier NCT00667810 ; registered 24 Apr 2008. Carriers (3001) ClinicalTrials.gov identifier NCT00676143 ; registered 2 May 2008. |
X Demographics
The data shown below were collected from the profiles of 6 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | 33% |
| United Kingdom | 1 | 17% |
| Unknown | 3 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 3 | 50% |
| Practitioners (doctors, other healthcare professionals) | 2 | 33% |
| Scientists | 1 | 17% |
Mendeley readers
The data shown below were compiled from readership statistics for 337 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | <1% |
| India | 1 | <1% |
| Belgium | 1 | <1% |
| Egypt | 1 | <1% |
| Unknown | 332 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 46 | 14% |
| Student > Bachelor | 45 | 13% |
| Researcher | 42 | 12% |
| Student > Master | 41 | 12% |
| Other | 18 | 5% |
| Other | 45 | 13% |
| Unknown | 100 | 30% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 50 | 15% |
| Neuroscience | 50 | 15% |
| Biochemistry, Genetics and Molecular Biology | 35 | 10% |
| Agricultural and Biological Sciences | 19 | 6% |
| Pharmacology, Toxicology and Pharmaceutical Science | 14 | 4% |
| Other | 54 | 16% |
| Unknown | 115 | 34% |
Attention Score in Context
This research output has an Altmetric Attention Score of 19. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 June 2021.
All research outputs
#1,669,381
of 23,313,051 outputs
Outputs from Alzheimer's Research & Therapy
#297
of 1,268 outputs
Outputs of similar age
#29,863
of 312,986 outputs
Outputs of similar age from Alzheimer's Research & Therapy
#3
of 11 outputs
Altmetric has tracked 23,313,051 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 92nd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,268 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 25.9. This one has done well, scoring higher than 76% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 312,986 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 90% of its contemporaries.
We're also able to compare this research output to 11 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 81% of its contemporaries.